• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

European Baby Care OEM RFQ Checklist: Which Age Group, Testing, Formula, and Packaging Details Matter?

Most European baby care projects do not fail at the formula stage — they fail at the RFQ stage. A brief that says "mild shampoo for babies, EU market, 200 ml" leaves the manufacturer…

Category: Mom & Baby Care Sourcing Guides • Author: laeyo • Published: 2026-11-02 • Views: 85

Most European baby care projects do not fail at the formula stage — they fail at the RFQ stage. A brief that says “mild shampoo for babies, EU market, 200 ml” leaves the manufacturer to assume the age band, the exposure scenario, the preservative strategy, the test panel and the pack format. Every one of those assumptions comes back later as a re-quote, a re-test, or a label that cannot be released. This checklist is built to be forwarded directly to a supplier so that the four decisions that carry the most cost and timeline — age group, testing, formula guardrails and packaging compatibility — are documented before a single sample is made.

What a European baby care RFQ must settle in the first 15 minutes

  • Age band is a formulation decision, not a marketing label. The age you declare drives exposure assumptions in the safety assessment, preservative and fragrance strategy, panel design and pack size.
  • In the EU there is no separate “baby product licence.” A baby cosmetic is a cosmetic under Regulation (EC) No 1223/2009, so the entire burden sits on the CPSR, the PIF, the GMP system and your claim substantiation file.
  • Three decisions set your cost floor: (1) age band per SKU, (2) whether the formula is a proven platform or a new development, (3) whether packaging is a stock format or a custom tool.
  • The fastest safe path: lock age band, pack format and claims wording first; optimise fragrance, texture and decoration later, after the safety and stability data are on track.
  • Request these five items immediately: EU Responsible Person confirmation, CPSR/PIF scope, challenge test (ISO 11930) and micro limits (ISO 17516), stability protocol including packaging compatibility, and the fragrance allergen + IFRA documentation matched to rinse-off vs leave-on use.

Informational only, not legal advice. Confirm requirements with your EU Responsible Person and safety assessor.

Decision 1 — Age group: the input that resets everything else

The declared age band changes the exposure calculation in the CPSR (children have a higher surface-area-to-body-weight ratio), the acceptable preservative and fragrance load, the wording of label warnings, and often the pack format and fill size. Pick one primary band per SKU and do not let marketing widen it later without re-opening the file.

Declared age band What typically changes in the formula What changes in testing What changes in packaging
0–3 months (newborn) Shortest possible ingredient list; fragrance-free is the usual buyer guardrail; minimal preservation strategy justified by the safety assessor Exposure scenario written for newborn use; irritation and eye-irritation data reviewed at higher scrutiny Small fill, precise dosing, no splash risk, clear “keep out of reach of children” area on the label panel
3–12 months Mild surfactant systems, pH aligned to tears, low or no fragrance Same core battery; panel must reflect sensitive-skin use, paediatric justification documented One-hand pump or flip-top, wet-hand grip, drop-resistant
12–36 months Can accept mild fragrance with full allergen declaration; richer emollients for barrier products Panel may include parents as users; consumer perception test becomes useful Larger fill becomes viable; refill consideration starts here
3–6 years More “fun” sensorial allowed; still held to child-use exposure Eye-irritation data matters more for shampoo (bathtime behaviour) Tamper-evident closures, ergonomic grip for small hands if child-operated
6–12 years Approaches adult mildness positioning but claims wording stays child-directed Standard adult-adjacent battery usually accepted Formats can follow adult range architecture

RFQ line to add: “Declared age band per SKU: ______. Confirm the exposure scenario used in the CPSR and the panel design that supports it.”

Decision 2 — The EU evidence pack to request before you discuss price

Ask for the documents, not the assurances. Each row below is a request you can paste into an email; the acceptance criteria stop the answer from being “we will provide later.”

Document / test Issued by What it proves Acceptance criteria
EU Responsible Person appointment Brand / importer, with named EU entity Legal basis for placing product on the EU market Signed mandate with name, EU address and contact before CPNP filing
CPSR + PIF Qualified safety assessor Product is safe for the declared age band and use Signed CPSR referencing this exact formula and pack; PIF index complete
CPNP notification Responsible Person Product notified before market placement CPNP reference number issued for this formulation
GMP certificate Manufacturing site Production under ISO 22716 Valid certificate naming the actual production site, not the trading office
Challenge test (ISO 11930) + micro limits (ISO 17516) Accredited lab Preservative system holds under the declared use Report on the final formula in the final pack, passing criteria met
Stability + packaging compatibility Manufacturer / lab Product remains compliant and functional in the pack over shelf life Accelerated plus real-time protocol, in-pack samples, pH/viscosity/micro/organoleptic checkpoints
Fragrance documentation: IFRA certificate (current amendment) + allergen declaration Fragrance house Fragrance is safe and correctly declared for the actual use IFRA category stated for the real use (rinse-off vs leave-on), allergens listed with percentages
Article 19 label pack Brand + RP review Label is complete in the language(s) of the selling member state(s) Approved artwork with INCI, nominal content, batch/PAO, warnings, RP name and address
Claim substantiation file Brand + lab Each claim is supported, not implied Claim-to-evidence mapping table signed off before artwork lock

Two points buyers regularly miss: fragrance allergen labelling under Regulation (EU) 2023/1545 runs with transition periods, so ask your RP for the applicable date for your SKU rather than assuming; and IFRA documentation is not a product approval — it supports one input and does not replace the CPSR.

Decision 3 — Testing: what actually substantiates mildness

  • Preservative efficacy: ISO 11930 challenge test on the final formula in the final container. Evidence: passing report dated against the launched formula.
  • Microbiological quality: ISO 17516 limits with batch-level data. Evidence: COA per batch showing micro results.
  • Skin irritation: in vitro reconstructed human epidermis (OECD TG 439) plus a clinical use test under dermatological control where the claim needs it. Evidence: reports naming the tested formula and panel.
  • Eye irritation: OECD TG 492 for “tear-free” or “no stinging” claims. Note that HET-CAM and RBC are screening tools, not a substitute for the substantiation your assessor will accept. Evidence: OECD-referenced report plus the claim wording it supports.
  • Sensitisation: OECD TG 442C/D/E on relevant ingredients or the formula, supporting “hypoallergenic” or sensitive-skin positioning. Evidence: report plus a written definition of what “hypoallergenic” means for this SKU.
  • Stability: accelerated (typically 12 weeks at elevated temperature) plus real-time, in the commercial pack. Evidence: protocol, raw data, conclusion on shelf life and PAO.
  • Consumer perception: a structured use test to support sensory and acceptability claims. Evidence: questionnaire, sample size, recruitment criteria, statistics.
  • Animal testing: confirmation that neither the finished product nor its ingredients were tested on animals for cosmetic purposes. Evidence: supplier declarations on file.

Practical constraint: infant panels are rare for ethical and practical reasons. Expect the dossier to rest on adult sensitive-skin panels plus a documented paediatric-use justification, unless you are commissioning an ethics-approved paediatric study — which adds months, not weeks.

Decision 4 — Formula guardrails to write into the brief

  • State the preservation philosophy explicitly: conventional preservation, “preservative-free” positioning with a documented hurdle strategy, or single-use formats. “Preservative-free” is a claim that needs a safety argument, not just an ingredient list.
  • Define fragrance intent in one of three ways: fragrance-free, unscented (may still contain masking raw materials — declare them), or fragranced with full allergen declaration.
  • Set pH and surfactant targets as numbers. “Mild” is not a specification; a pH window and a surfactant-class restriction are.
  • Restrict colourants to those permitted under the EU Annexes and confirm no nanomaterial is present unless it has been assessed and notified.
  • Ask for the impurity profile: 1,4-dioxane in ethoxylated raw materials, formaldehyde releasers, nitrosamine risk, heavy metals. Evidence: raw material spec sheets and COAs.
  • Handle “natural” claims carefully. If you claim natural origin, request the ISO 16128 calculation; if you claim a hero botanical, request origin documentation and batch-to-batch consistency data, because trending botanicals are exactly where supply-chain substitution happens.

Decision 5 — Packaging: the compatibility questions that decide the launch

  • Dose accuracy: what volume does the pump deliver per stroke with your viscosity, and what is the tolerance across the batch?
  • Wet-hand and one-hand use: has the closure been tested by users with wet hands, or only in a lab?
  • Chemical compatibility: has the formula been stored in the actual resin (PP, PE, PET, PCR content) for the full accelerated period, with organoleptic and weight-loss checks? Fragrance absorption into plastic and plasticiser migration are the two quiet failures.
  • Label durability: adhesion and ink resistance after humidity and repeated wet handling — bathrooms are the harshest environment your label will ever meet.
  • Transport: drop and vibration testing (for example ISTA 3A) on the filled, closed pack.
  • Sustainability claims: if you claim recycled content, refill or recyclability, request the material declaration and the recyclability assessment. In the EU a vague “green” claim is a compliance risk, not a marketing win.
  • Speed vs customisation: for first launches, stock bottle plus stock pump plus standard label or silk screen will almost always beat a custom mould on time, MOQ and cost stability.

Fast self-check decision tree

  • Start here: if you have a proven platform formula and a stock pack, go straight to compatibility and stability in that pack — this is the fastest safe route.
  • If the age band is 0–12 months, treat fragrance, preservation and exposure as fixed constraints and design the brief around them.
  • If you need a “tear-free” or “hypoallergenic” claim, add OECD-referenced eye and sensitisation testing to the plan before artwork, not after.
  • If packaging is a custom tool, add tooling lead time and a second stability cycle in the final pack to the critical path.
  • If you sell in more than one member state, lock the language set before artwork: multilingual panels drive font size, panel area and often the fill volume.
  • If the product carries SPF or any medicinal-sounding benefit, stop and re-scope — the test package and claims rules change materially.
  • Boundary cases needing specialist input: products positioned close to medical devices, wipes with biocidal or disinfecting intent, products for premature infants, and any claim that implies treatment of a condition. Route these to your RP and regulatory counsel before sampling.

Realistic timeline: two paths

Phase Fastest safe path Standard path Evidence output
Brief and age-band lock 1 week 2 weeks Signed brief with age band, claims list, pack direction
Formula selection Platform formula, 1–2 weeks New development, 4–6 weeks Formula spec sheet, INCI, allergen calculation
Packaging lock Stock pack, 1–2 weeks Custom tool, 6–10 weeks Pack spec, compatibility protocol, decoration proofs
Lab batch and stability start 1 week 2 weeks Batch record, stability protocol with in-pack samples
Challenge and micro testing 4–6 weeks (cannot compress) 4–6 weeks ISO 11930 and ISO 17516 reports
Stability read-out Accelerated, 12 weeks, run in parallel Accelerated plus real-time data before launch Data tables, conclusion on shelf life and PAO
Label and claims review 2 weeks, running parallel to stability 3 weeks including RP review Approved multilingual artwork, claim-to-evidence map
CPSR and PIF 2–3 weeks after data package closes 3–4 weeks Signed CPSR, complete PIF
CPNP notification 1 week 1–2 weeks CPNP reference number
Pilot and first production 3–4 weeks 4–6 weeks Pilot report, batch COA, retained samples

Compression comes from parallelising and from using a proven platform formula in a stock pack. It does not come from shortening challenge testing or launching without stability data — those are the two delays that become recall costs.

Common failure modes

1. Pump delivers the wrong dose

Symptom: the first production samples dispense too much or too little, or dose drifts across the run.
Root cause: pump specified against water rather than the actual viscosity and density; no dose testing on the real formula.
Prevention: dose-accuracy testing on filled units at start, middle and end of the run.
What to request from factory (evidence): dose measurement report (ml per stroke, tolerance) on the final formula in the final pack.

2. Label lifting in the bathroom

Symptom: edges curl or ink smears within weeks of consumer use.
Root cause: adhesive chosen for dry-room conditions; wrong surface-energy match to the resin; incompatible decoration method.
Prevention: humidity and wet-hand adhesion testing on decorated units before artwork lock.
What to request from factory (evidence): label adhesion and rub-resistance test report on the commercial substrate, plus the packaging supplier’s material declaration.

3. Fragrance interacts with the pack

Symptom: scent fades or turns in the bottle; product near the shoulder smells different from product near the base.
Root cause: fragrance components absorbing into the resin or interacting with a plasticiser; no in-pack organoleptic stability.
Prevention: in-pack stability with sensory panel checks at each checkpoint, not just pH and viscosity.
What to request from factory (evidence): stability report including organoleptic evaluation at each interval, with the pack material named.

4. Documentation set is incomplete at launch

Symptom: retailer or marketplace asks for CPSR, COA or the allergen declaration and the file is missing or refers to a different formula version.
Root cause: documents produced at sampling stage and never updated to the commercial formula and pack; no document control.
Prevention: a single document register with version numbers tied to the launched formula code.
What to request from factory (evidence): document register listing CPSR, PIF index, COA, SDS, stability, micro, IFRA and allergen documents, each referencing the final formula code.

5. INCI on artwork does not match the batch

Symptom: label lists ingredients in the wrong order or omits a raw material present in production.
Root cause: artwork frozen before the formula was finalised; no reconciliation step.
Prevention: a formal artwork-to-formula reconciliation signed by the manufacturer before printing.
What to request from factory (evidence): signed reconciliation sheet comparing the printed INCI to the batch formula, per SKU.

6. Claim outruns the evidence

Symptom: “tear-free”, “hypoallergenic” or a percentage claim cannot be defended when challenged.
Root cause: claims written by marketing after the test plan was fixed; unclear definitions.
Prevention: claim-to-evidence mapping completed before artwork, with each claim defined in writing.
What to request from factory (evidence): claim substantiation table linking each on-pack claim to a specific report, plus the definition used.

7. Multilingual panel does not fit the pack

Symptom: mandatory information becomes unreadable at final print size, or warnings are dropped to make room.
Root cause: pack chosen before the language set was confirmed.
Prevention: test the full language set at final font size on the actual label area, including the thumbnail view for e-commerce.
What to request from factory (evidence): artwork proof at 1:1 scale with the complete mandatory text, plus RP sign-off.

8. Microbial failure on the first production batch

Symptom: challenge test passed at lab scale but finished batches show out-of-spec micro results.
Root cause: process water quality, filling hygiene or a raw material supplier change after testing.
Prevention: change control on raw materials and environmental monitoring at filling.
What to request from factory (evidence): batch COA with micro results, environmental monitoring records, and written change-control procedure.

Do NOT cut: red lines for baby care

  • Do not skip the challenge test on the final formula in the final pack — a preservative system proven in a beaker is not proven in a 300 ml bottle.
  • Do not launch without stability data covering the declared shelf life and PAO.
  • Do not print a label without a signed CPSR and a completed Article 19 checklist in the correct language(s).
  • Do not accept a fragrance without IFRA documentation matched to the real use category and a full allergen declaration.
  • Do not allow “hypoallergenic”, “tear-free”, “from day one” or percentage claims without a defined claim and a matching report.
  • Do not treat a stock certificate as site evidence — confirm the GMP certificate names the actual production site.
  • Do not substitute a raw material after stability or micro testing without re-testing.

Copy-paste RFQ checklist

Share: declared age band per SKU and the intended use scenario.
Share: target member states and the required label language set.
Confirm: EU Responsible Person name, EU address and mandate status.
Confirm: whether a CPSR and full PIF will be delivered for this exact formula.
Provide: packaging direction (stock or custom), fill volume and closure type.
Provide: claim list with proposed on-pack wording for each claim.
Attach: fragrance brief or confirmation that the product is fragrance-free.
Confirm: preservation philosophy and whether a preservative-free claim is intended.
Lock: pH window, surfactant class restriction and viscosity target as numbers.
Lock: shelf life and PAO targets before stability starts.
Test: challenge test to ISO 11930 on the final formula in the final pack.
Test: micro quality to ISO 17516 with per-batch COA.
Test: in vitro skin irritation (OECD TG 439) and eye irritation (OECD TG 492) if claims require.
Test: sensitisation data (OECD TG 442C/D/E) supporting hypoallergenic positioning.
Test: stability including in-pack packaging compatibility with organoleptic checks.
Test: dose accuracy, drop and transport testing on filled units.
Test: label adhesion and rub resistance under humidity and wet-hand use.
Provide: IFRA certificate at the current amendment, matched to rinse-off or leave-on use.
Provide: fragrance allergen declaration with percentages against the regulatory thresholds.
Review: artwork at 1:1 scale with complete mandatory text in every language.
Approve: claim-to-evidence mapping table before artwork lock.
Approve: artwork-to-formula reconciliation signed by the manufacturer.
Confirm: no animal testing on finished product or ingredients for cosmetic purposes.
Provide: document register with version numbers tied to the launched formula code.
Confirm: raw material change-control procedure and notification commitment.
Confirm: pilot run date, first production lead time and MOQ per SKU.

FAQ

Is a baby cosmetic a separate regulatory category in the EU?

No. It is a cosmetic under Regulation (EC) No 1223/2009 like any other. What changes is scrutiny: the safety assessment must reflect child exposure for the declared age band, and claims directed at babies attract closer attention from authorities and retailers. Plan for a stricter file, not a different file.

Can we claim “tear-free” without eye irritation testing?

Not defensibly. “Tear-free” has no legal definition in the EU, so it is a claim you must substantiate. Build an OECD-referenced in vitro eye irritation dataset plus pH data, and write down exactly what the claim means for your SKU before the artwork is approved.

How long does the EU documentation take for a baby care launch?

Typical standard path is 16–24 weeks from brief to first production, dominated by challenge testing (4–6 weeks) and accelerated stability (about 12 weeks). A proven platform formula in a stock pack can bring this to roughly 10–13 weeks by parallelising, but the test read-outs themselves cannot be shortened.

Do we need separate stability testing for refill packs?

Yes. A refill pouch has a different surface-to-volume ratio, a different closure and different headspace behaviour. Treat it as a separate pack for compatibility and stability, and keep the refill fitment verified against the parent bottle.

What is the single most common cause of re-quotes?

An RFQ that omits the age band or the language set. Both change the formulation envelope, the panel design and the label area, so the manufacturer prices a guess and revises when the real requirement appears.

Next step

Send your age band, member states, pack direction and target launch date together — those four inputs let a manufacturer quote realistically instead of quoting a placeholder. If you want the RFQ reviewed against EU documentation requirements before you commit to a sample round, Request a Quote and include your SKU list, formats, positioning and timeline target for a faster response.

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).